Index. urologic.theclinics.com. Note: Page numbers of article titles are in boldface type.

Transcription

1 Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with LUTS, 293 and prevalence of BPH associated with LUTS, 291 Alpha-blockers, for treatment of BPH, , 352, , 398 versus 5-alpha reductase inhibitors for LUTS and, in combination with 5-alpha-reductase inhibitors, development of selective, efficacy of different class formulations, 352 sexual side effects of, , 398 in combinations with 5-alpha-reductase inhibitors, 398 comparisons of, 395 nonselective, 394 selective, Alpha-reductase inhibitors, 5-, for treatment of LUTS and BPH, , , versus alpha-blockers for LUTS/BPH, with alpha-blockers, with phosphodiesterase type 5 inhibitors, 332 effects on PSA and prostate cancer risk, 328 efficacy of different class formulations, dutasteride, finasteride, sexual side effects of, in combination with alpha blockers, 398 physiologic basis to sexual dysfunction, 396 study-specific outcomes, American Urological Association, guidelines for diagnostic work-up of LUTS, 305, Urol Clin N Am 43 (2016) /16/$ see front matter Anatomy, of human and rodent prostate, Androgens, interaction with BPH, Animal models, in study of BPH, Anticholinergics, efficacy of different class formulations, 353 sexual side effects of BPH treatment with, 398 Antimuscarinics, for treatment of LUTS, clinical efficacy, clinical safety, mechanisms of action, 338 B Benign prostatic hyperplasia (BPH), 5-alpha-reductase inhibitors, with alpha-blockers, with phosphodiesterase type 5 inhibitors, 332 effects on PSA and prostate cancer risk, 328 dutasteride, finasteride, alpha-blockers for treatment of, versus 5-alpha reductase for LUTS and, development of, associated with LUTS, epidemiology of, efficacy of different class formulations in medical management of, phosphodiesterase type 5 inhibitors, urologic.theclinics.com

2 414 Index Benign (continued) treatment resistance and complications, 354 prostate anatomy, embryology and etiology of, anatomy of human and rodent prostate, animal models in study of, etiology, human and rodent prostate embryology, prostatic urethral lift for LUTS secondary to, sexual side effects of treatments, medications, surgical treatments, testosterone and the prostate, androgens and interaction with BPH, Benign prostatic obstruction, choosing treatment for, Beta-3 agonists, for treatment of LUTS, , 353 clinical efficacy, 341 clinical safety, efficacy of different class formulations, 353 mechanism of action, 341 Bladder outlet obstruction, alpha-blockers for treatment of LUTS in BPH, C Canadian Urological Association, guidelines for diagnostic work-up of LUTS, Creatinine, serum, in diagnostic work-up of LUTS, 301 D Dutasteride, E Ejaculatory dysfunction, sexual side effects of BPH Embryology, of human and rodent prostate, Endoscopy, in diagnostic work-up of LUTS, Epidemiology, of BPH associated with LUTS, Erectile dysfunction, sexual side effects of BPH Ethnicity, and incidence of BPH associated with LUTS, 293 and prevalence of BPH associated with LUTS, 292 European Association of Urology, guidelines for diagnostic work-up of LUTS, F Finasteride, Frequency-volume charts, in work-up of LUTS, 300 G Greenlight photovaporization, of the prostate, Guidelines, for diagnostic work-up of LUTS, 305, American Urologic Association, 305, Canadian Urological Association, 307 European Association of Urology, 306 H History, patient, in diagnostic work-up of LUTS, additional history, 300 frequency-volume charts, 300 symptom score, Holmium laser enucleation, of prostate, , 400 complications, 380 functional results, 380

3 Index 415 indications, 380 learning curve, Hypogonadism, natural history of testosterone and, I Imaging, in diagnostic work-up of LUTS, Incidence, of BPH associated with LUTS, by age and severity, 293 overall, by race and ethnicity, 293 International Prostate Symptom Score (IPSS), L Laser enucleation, holmium, of prostate, , 400 complications, 380 functional results, 380 indications, 380 learning curve, Lower urinary tract symptoms (LUTS), antimuscarinics for, beta-3 agonists for, diagnostic work-up of, guideline overview, imaging and additional testing, additional imaging, 306 endoscopy, peak urine flow rate, postvoid residual urine volume, 302 pressure-flow studies, prostate ultrasonography, prostate-specific antigen, serum creatinine, 301 urine studies, patient history, additional history, 300 frequency-volume charts, 300 symptom score, physical examination, 300 efficacy of different class formulations in medical management of, phosphodiesterase type 5 inhibitors, treatment resistance and complications, 354 epidemiology of BPH associated with, phosphodiesterase inhibitors for, prostatic urethral lift for LUTS secondary to BPH, testosterone and the prostate, LUTS. See Lower urinary tract symptoms. M Medical management, of LUTS and BPH, 5-alpha-reductase inhibitors, effects on PSA and prostate cancer risk, 328 alpha-blockers for treatment of, versus 5-alpha reductase for LUTS and, development of, efficacy of different class formulations, phosphodiesterase type 5 inhibitors, treatment resistance and complications, 354 sexual side effects of, Microwave therapy, transurethral, for BPH, sexual side effects of, 400 Minimally invasive therapy, prostatic urethral lift,

4 416 Index N Needle ablation, transurethral, for BPH, sexual side effects of, 400 O Obstruction, benign prostatic, choosing treatment for, bladder outlet, alpha-blockers for treatment of, Overactive bladder, antimuscarinics for, beta-3 agonists for, phosphodiesterase inhibitors for, P Peak urine flow rate, in diagnostic work-up of LUTS, Phosphodiesterase type 5 inhibitors, in combination with 5-alpha-reductase inhibitors, 332 efficacy of different class formulations, sexual side effects of, 398 for treatment of LUTS, , 398 clinical efficacy, 343 clinical safety, mechanism of action, Photoselective vaporization, of prostate, sexual side effects of, Photovaporization, greenlight, of the prostate, Physical examination, in diagnostic work-up of LUTS, 300 Postvoid residual urine volume, in diagnostic work-up of LUTS, 302 Pressure-flow studies, in diagnostic work-up of LUTS, Prevalence, of BPH associated with LUTS, by disease severity, overall and by age, 291 by race and ethnicity, 292 Proscar. See Finasteride. Prostate, anatomy of, benign prostatic hyperplasia, etiology of, embryology and postnatal development of, testosterone and, ultrasonography of, in diagnostic work-up of LUTS, Prostate cancer, effects of 5-alpha-reductase inhibitors on risk of, 328 Prostate-specific antigen (PSA), effects of 5-alpha-reductase inhibitors on, 328 Prostatectomy, open simple, sexual side effects of, 400 robotic-assisted simple, complications, 389 cost comparison, 389 duration of catheterization, 389 functional, 389 hospital duration of stay, 389 operative blood loss and transfusion, 389 operative time, advancement of bladder neck mucosa, 387 bladder closure, 387 development of lateral and anterior plane, 387 development of posterior plane, patient setup, 386 postoperative care, 387 preoperative evaluation and preparation, 386 prostate exposure, 386 transection of urethra and removal of adenoma, 387 Prostatic hyperplasia, benign. See Benign prostatic hyperplasia (BPH). Prostatic obstruction, benign. See Benign prostatic obstruction (BPO). Prostatic urethral lift, for LUTS secondary to BPH,, 400 durability, 377 effectiveness, safety, sexual function preservation, immediate postoperative care, preoperative planning, preparation and patient positioning, 359 procedure, surgical approach, R Race, and incidence of BPH associated with LUTS, 293 and prevalence of BPH associated with LUTS, 292 Rats, anatomy of prostate in, in animal models for study of BPH,

5 Index 417 embryology of prostate in, Risk factors, for BPH associated with LUTS, Robotic-assisted simple prostatectomy, complications, 389 cost comparison, 389 duration of catheterization, 389 functional, 389 hospital duration of stay, 389 operative blood loss and transfusion, 389 operative time, advancement of bladder neck mucosa, 387 bladder closure, 387 development of lateral and anterior plane, 387 development of posterior plane, patient setup, 386 postoperative care, 387 preoperative evaluation and preparation, 386 prostate exposure, 386 transection of urethra and removal of adenoma, 387 S Serum creatinine, in diagnostic work-up of LUTS, 301 Sexual function, preservation of, with prostatic urethral lift, Sexual side effects, of BPH medications, surgical treatments, Silodosin, for LUTS in BPH, Simple prostatectomy. See Prostatectomy. Storage lower urinary tract symptoms, antimuscarinics for, beta-3 agonists for, phosphodiesterase inhibitors for, Surgical management, of benign prostatic obstruction, of LUTS and BPH, prostatic urethral lift, T sexual side effects, Testosterone, and the prostate, Transurethral microwave therapy, for BPH, sexual side effects of, 400 Transurethral needle ablation, for BPH, sexual side effects of, 400 Transurethral resection of prostate (TURP), bipolar, for BPO, 379 complications, 379 functional results, 379 indications, 379 learning curve, 379 for BPH, sexual side effects of, bipolar versus monopolar, ejaculatory dysfunction, 399 erectile dysfunction, 399 monopolar, for BPO, complications, functional results, 378 indications, 378 learning curve, 379 U Ultrasonography, of prostate, in diagnostic work-up of LUTS, Urinary retention, acute, alpha-blockers for treatment of, 317 Urine studies, in diagnostic work-up of LUTS, V Vaporization, photoselective, of prostate, sexual side effects of, Voiding diaries, in work-up of LUTS, 300